Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell Carcinoma
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.16379
Abstract: Key Points Question Do contemporary first-line therapy options for metastatic renal cell carcinoma (mRCC) have different likelihoods of objective imaging response (complete or partial response), and is objective imaging response associated with overall survival? Findings… read more here.
Keywords: oncology; cell carcinoma; renal cell; imaging response ... See more keywords
Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.4679
Abstract: Immune checkpoint inhibitor/tyrosine kinase inhibitor (ICI/TKI) combinations are a new standard of care for the initial treatment of metastatic renal cell carcinoma (mRCC). Their efficacy and toxicity beyond the first‐line setting remain poorly defined. read more here.
Keywords: cell carcinoma; inhibition; renal cell; immune checkpoint ... See more keywords
A phase II study of alternating sunitinib and temsirolimus therapy in patients with metastatic renal cell carcinoma.
Sign Up to like & getrecommendations! Published in 2023 at "Cancer medicine"
DOI: 10.1002/cam4.5990
Abstract: BACKGROUND Sunitinib is a multi-target tyrosine kinase inhibitor (TKI) that inhibits VEGF receptor 1, 2, 3 (VEGFRs), platelet-derived growth factor receptor (PDGFR), colony-stimulating factor receptor (CSFR), and the stem cell factor receptor c-KIT. Temsirolimus inhibits… read more here.
Keywords: alternating sunitinib; cell; metastatic renal; therapy ... See more keywords
Sarcopenia and systemic inflammation are associated with decreased survival after cytoreductive nephrectomy for metastatic renal cell carcinoma
Sign Up to like & getrecommendations! Published in 2022 at "Cancer"
DOI: 10.1002/cncr.34174
Abstract: This study was aimed at assessing the associations of sarcopenia, muscle density, adiposity, and inflammation with overall survival (OS) after cytoreductive nephrectomy (CN) for metastatic renal cell carcinoma. read more here.
Keywords: cell carcinoma; renal cell; metastatic renal; cytoreductive nephrectomy ... See more keywords
Weight and skeletal muscle loss with cabozantinib in metastatic renal cell carcinoma
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Cachexia, Sarcopenia and Muscle"
DOI: 10.1002/jcsm.13021
Abstract: Cabozantinib, a standard of care metastatic renal cell carcinoma (mRCC), may be associated with weight and muscle loss. These effects of new generation VEGFR tyrosine kinase inhibitor on muscle mass loss are poorly described. read more here.
Keywords: cell carcinoma; renal cell; metastatic renal; loss ... See more keywords
Metastatic renal cell carcinoma to the pancreas: Clinical features and treatment outcome
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Surgical Oncology"
DOI: 10.1002/jso.26251
Abstract: Metastatic renal cell carcinoma to the pancreas (PM‐RCC) is infrequent; we sought to describe the characteristics of PM‐RCC and analyze the outcome following treatment. read more here.
Keywords: cell carcinoma; renal cell; carcinoma pancreas; metastatic renal ... See more keywords
Feasibility of therapeutic drug monitoring of sunitinib and its implications on response and toxicity in patients with metastatic renal cell cancer
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-022-04432-4
Abstract: Sunitinib is an oral tyrosine kinase inhibitor approved for the treatment of metastatic renal cell carcinoma (mRCC). High variability in pharmacokinetics coupled with a proven exposure–effect relationship makes sunitinib an ideal candidate for therapeutic drug… read more here.
Keywords: feasibility; response; renal cell; toxicity ... See more keywords
Prognostic value of the Glasgow Prognostic Score for patients with metastatic renal cell carcinoma treated by cytoreductive nephrectomy
Sign Up to like & getrecommendations! Published in 2017 at "International Journal of Clinical Oncology"
DOI: 10.1007/s10147-017-1221-z
Abstract: BackgroundThe aim of the present study was to evaluate the prognostic significance of the Glasgow Prognostic Score (GPS) in metastatic renal cell carcinoma (mRCC) patients treated by cytoreductive nephrectomy (CN), and the accuracy of the… read more here.
Keywords: glasgow prognostic; prognostic score; gps; metastatic renal ... See more keywords
External validation of the systemic immune-inflammation index as a prognostic factor in metastatic renal cell carcinoma and its implementation within the international metastatic renal cell carcinoma database consortium model
Sign Up to like & getrecommendations! Published in 2018 at "International Journal of Clinical Oncology"
DOI: 10.1007/s10147-018-01390-x
Abstract: BackgroundWe conducted a study to validate the influence of the systemic immune-inflammation index (SII) on overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC) and to verify whether the implementation of the SII… read more here.
Keywords: renal cell; model; cell carcinoma; metastatic renal ... See more keywords
Clinical outcomes of second-line treatment following prior targeted therapy in patients with metastatic renal cell carcinoma: a comparison of axitinib and nivolumab
Sign Up to like & getrecommendations! Published in 2020 at "International Journal of Clinical Oncology"
DOI: 10.1007/s10147-020-01708-8
Abstract: Sequential treatment starting with target therapy is still the standard care for metastatic renal cell carcinoma (mRCC), even in the era of immune checkpoint inhibitors. Our objective was to compare the clinical outcomes between axitinib… read more here.
Keywords: targeted therapy; treatment; metastatic renal; therapy ... See more keywords
Prognosis of Japanese metastatic renal cell carcinoma patients in the targeted therapy era
Sign Up to like & getrecommendations! Published in 2021 at "International Journal of Clinical Oncology"
DOI: 10.1007/s10147-021-01979-9
Abstract: The aims of this study were to investigate prognosis and validate prognostic models [Memorial Sloan-Kettering Cancer Center (MSKCC), International Metastatic Renal Cell Carcinoma Data Consortium (IMDC), and Japanese metastatic renal cancer (JMRC) models] in the… read more here.
Keywords: renal cell; era; cell carcinoma; targeted therapy ... See more keywords